Chowdhury Ahsan, MD
Cardiovascular Disease · Las Vegas, NVNPI 1164502225
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Medtronic at 29.1% of the total. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $96.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
- Cvrx, Inc.$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Abbott$2K
- Abiomed$2K
- plus $9K from 33 others
Across 250 payments — averaging $5418.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$633K
- Abbott$178K
- Livanova USA, Inc.$166K
- CSL Behring$155K
- Novartis$115K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$35K
- plus $73K from 3 others
What the payments were for
- Consulting fees$5,03312%
- Speaking & faculty fees$7,50018%
- Travel & lodging$12,56330%
- Food & beverage$15,85438%
- Education$2891%
- Gifts$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$8,650
- Barostim Neo System$4,154
- CAMZYOS$2,333
- PASCAL$987
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$941
- Carto 3$932
- CARDIOMEMS$394
- AVEIR$204
- HeartMate 3 Left Ventricular Dev$175
- FFRangio$174
- SYMPLICITY G3$167
- CoreValve Evolut$165
- OCTARAY MAPPING CATHETER$150
- Soundstar$150
- NUVISION ICE CATHETER$150
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$147
- VISITAG SURPOINT External Processing Unit$146
- Edwards SAPIEN 3 Transcatheter Heart Valve$132
- Cleerly Ischemia$129
- Cleerly Labs$129
How this compares
$41,259 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $159,742 |
| EntrestoSacubitril/Valsartan | 82 | $128,996 |
| BrilintaTicagrelor | 46 | $40,397 |
| Repatha SureclickEvolocumab | 16 | $18,045 |
| VascepaIcosapent Ethyl | 31 | $16,131 |
| XareltoRivaroxaban | 16 | $14,095 |
| Metoprolol Tartrate | 268 | $2,137 |
| Rosuvastatin Calcium | 118 | $1,905 |
| Carvedilol | 197 | $1,477 |
| Losartan Potassium | 159 | $1,294 |
| Atorvastatin Calcium | 143 | $1,251 |
| ClopidogrelClopidogrel Bisulfate | 110 | $1,223 |
| Ezetimibe | 50 | $1,107 |
| Amlodipine Besylate | 156 | $999 |
| Ranolazine ErRanolazine | 13 | $948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $114 | $159,742129 claims |
| NovartisEntresto | $326 | $128,99682 claims |
| AstraZenecaBrilinta | $242 | $40,39746 claims |
| Johnson & JohnsonXarelto | $90 | $14,09516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
- Dalia HawwassLas Vegas$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.